Breaking News Instant updates and real-time market news.

ADMP

Adamis Pharmaceuticals

$0.62

-0.6734 (-52.20%)

07:56
11/26/19
11/26
07:56
11/26/19
07:56

Adamis Pharmaceuticals downgraded to Hold from Buy at Maxim

As previously reported, Maxim analyst Jason McCarthy downgraded Adamis Pharmaceuticals to Hold from Buy after the company disclosed an FDA complete response letter on its high-dose naloxone product for opioid overdoses. The analyst notes that he is now awaiting clarity on the path forward for Adamis Pharmaceuticals, even though the letter raised no clinical safety or efficacy issues outside of its questions regarding Chemistry, Manufacturing and Controls. McCarthy adds however that the company's cash position of $12.1M reported earlier this month is "low".

ADMP Adamis Pharmaceuticals
$0.62

-0.6734 (-52.20%)

07/23/19
RILY
07/23/19
UPGRADE
Target $1.1
RILY
Neutral
B. Riley FBR upgrades Adamis to Neutral, keeps $1.10 price target
As previously reported, B. Riley FBR analyst Andrew D'Silva upgraded Adamis Pharmaceuticals (ADMP) to Neutral from Sell after the stock declined to his $1.10 price target, which he maintains. He continues to worry that the PDUFA date for its naloxone candidate could be delayed and expects a slower than initially expected ramp up for its EpiPen alternative that is marketed by Novartis' (NVS) Sandoz unit, D'Silva tells investors.
11/25/19
MAXM
11/25/19
DOWNGRADE
MAXM
Hold
Adamis Pharmaceuticals downgraded to Hold from Buy at Maxim
Maxim analyst Jason McCarthy downgraded Adamis Pharmaceuticals to Hold from Buy.
11/25/19
RAJA
11/25/19
DOWNGRADE
RAJA
Market Perform
Adamis Pharmaceuticals cut to Market Perform from Outperform at Raymond James
Raymond James analyst Elliot Wilbur downgraded Adamis Pharmaceuticals to Market Perform from Outperform.
11/26/19
RAJA
11/26/19
DOWNGRADE
RAJA
Market Perform
Adamis Pharmaceuticals downgraded to Market Perform after CRL at Raymond James
As previously reported, Raymond James analyst Elliot Wilbur downgraded Adamis Pharmaceuticals to Market Perform from Outperform following the disclosure of a complete response letter from the FDA on its high-dose naloxone product for opioid overdoses, ZIMHI. While issues raised by the FDA in Chemistry, Manufacturing and Controls "are almost always resolvable," Adamis doesn't have sufficient funding to carry it beyond the next 9-12 months, Wilbur tells investors. 95% of all CMC-related CRLs are eventually approved and a 9-12 month horizon for resubmission and approval "would fall in the range of feasible," Wilbur added, however.

TODAY'S FREE FLY STORIES

OEZVY

Verbund

$0.00

(0.00%)

05:28
12/12/19
12/12
05:28
12/12/19
05:28
Upgrade
Verbund rating change  »

Verbund upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALV

Autoliv

$83.17

0.81 (0.98%)

05:25
12/12/19
12/12
05:25
12/12/19
05:25
Upgrade
Autoliv rating change  »

Autoliv upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

AMGN

Amgen

$233.96

0.14 (0.06%)

05:25
12/12/19
12/12
05:25
12/12/19
05:25
Hot Stocks
Amgen, UCB announce EC approval of EVENITY »

Amgen and UCB announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KR

Kroger

$28.03

0.14 (0.50%)

05:25
12/12/19
12/12
05:25
12/12/19
05:25
Upgrade
Kroger rating change  »

Kroger upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMWYY

BMW

$0.00

(0.00%)

05:23
12/12/19
12/12
05:23
12/12/19
05:23
Upgrade
BMW rating change  »

BMW upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$49.60

0.43 (0.87%)

05:23
12/12/19
12/12
05:23
12/12/19
05:23
Upgrade
Charles Schwab rating change  »

Charles Schwab upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVKIF

Evonik

$0.00

(0.00%)

05:22
12/12/19
12/12
05:22
12/12/19
05:22
Upgrade
Evonik rating change  »

Evonik upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SOLVY

Solvay

$0.00

(0.00%)

05:22
12/12/19
12/12
05:22
12/12/19
05:22
Downgrade
Solvay rating change  »

Solvay downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SOLVY

Solvay

$0.00

(0.00%)

05:21
12/12/19
12/12
05:21
12/12/19
05:21
Upgrade
Solvay rating change  »

Solvay upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$86.59

0.56 (0.65%)

05:19
12/12/19
12/12
05:19
12/12/19
05:19
Upgrade
Starbucks rating change  »

Starbucks upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWI

SolarWinds

$18.28

0.1 (0.55%)

05:19
12/12/19
12/12
05:19
12/12/19
05:19
Recommendations
SolarWinds analyst commentary  »

SolarWinds remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAKE

Cheesecake Factory

$40.73

-0.77 (-1.86%)

05:14
12/12/19
12/12
05:14
12/12/19
05:14
Initiation
Cheesecake Factory initiated  »

Cheesecake Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXRH

Texas Roadhouse

$57.25

0.55 (0.97%)

05:13
12/12/19
12/12
05:13
12/12/19
05:13
Initiation
Texas Roadhouse initiated  »

Texas Roadhouse initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

DRI

Darden

$117.44

-1.15 (-0.97%)

05:11
12/12/19
12/12
05:11
12/12/19
05:11
Initiation
Darden initiated  »

Darden initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

EAT

Brinker

$41.12

-0.225 (-0.54%)

05:09
12/12/19
12/12
05:09
12/12/19
05:09
Initiation
Brinker initiated  »

Brinker initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLMN

Bloomin' Brands

$21.95

-0.065 (-0.30%)

05:08
12/12/19
12/12
05:08
12/12/19
05:08
Initiation
Bloomin' Brands initiated  »

Bloomin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$9.62

0.62 (6.89%)

05:05
12/12/19
12/12
05:05
12/12/19
05:05
Downgrade
Bright Scholar rating change  »

Bright Scholar downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$88.09

0.165 (0.19%)

04:59
12/12/19
12/12
04:59
12/12/19
04:59
Recommendations
Wayfair analyst commentary  »

Wayfair price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

MD

Mednax

$26.75

1.975 (7.97%)

04:56
12/12/19
12/12
04:56
12/12/19
04:56
Upgrade
Mednax rating change  »

Mednax upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNFT

Genfit

$15.38

-0.805 (-4.97%)

04:55
12/12/19
12/12
04:55
12/12/19
04:55
Conference/Events
Roth Capital healthcare analyst to hold an analyst/industry conference call »

Healthcare Analyst Rahimi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 18

    Dec

WCN

Waste Connections

$90.15

-0.03 (-0.03%)

04:55
12/12/19
12/12
04:55
12/12/19
04:55
Conference/Events
Waste Connections participates in a conference call with UBS »

Environmental Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

04:55
12/12/19
12/12
04:55
12/12/19
04:55
Conference/Events
JPMorgan software technology analyst to hold an analyst/industry conference call »

Software Technology…

DNOW

NOW Inc.

$11.22

0.195 (1.77%)

04:55
12/12/19
12/12
04:55
12/12/19
04:55
Conference/Events
NOW Inc. management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 19

    Feb

MASI

Masimo

$154.28

1.62 (1.06%)

04:55
12/12/19
12/12
04:55
12/12/19
04:55
Conference/Events
Masimo management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

04:55
12/12/19
12/12
04:55
12/12/19
04:55
General news
PPI-FD to be reported at 08:30 »

November PPI-FD will be…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.